Toll Free: 1-888-928-9744

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 50 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Pipeline Review, H1 2016', provides in depth analysis on Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted pipeline therapeutics. 

The report provides comprehensive information on the Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11)
- The report reviews Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) Overview 6 Therapeutics Development 7 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Products under Development by Stage of Development 7 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Products under Development by Therapy Area 8 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Products under Development by Indication 9 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Products under Development by Companies 12 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Companies Involved in Therapeutics Development 20 Novartis AG 20 Pharmaleads SA 21 Theravance Biopharma, Inc. 22 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Drug Profiles 23 (sacubitril + valsartan) - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 PL-265 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 PL-37 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 STR-324 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 TD-0714 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Dormant Projects 35 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Discontinued Products 36 Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Featured News & Press Releases 37 Apr 26, 2016: NICE gives green light to new drug set to benefit 100,000 people with common heart condition 37 Apr 02, 2016: New analyses show Novartis' Entresto reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless 38 Mar 09, 2016: Theravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Study of TD-0714, an Inhibitor of Neprilysin 38 Jan 20, 2016: Breakthrough drug for heart failure now available in the UK 39 Dec 08, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-0714, an Inhibitor of Neprilysin 40 Dec 02, 2015: New heart failure therapy projected to increase life expectancy 41 Nov 24, 2015: Novartis' heart failure medicine Entresto receives EU approval 42 Nov 10, 2015: Novartis heart failure medicine Entresto substantially cuts 30-day hospital readmissions, new post-hoc analysis shows 42 Oct 13, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-0714, an Inhibitor of Neprilysin 43 Oct 06, 2015: Heart failure treatment ENTRESTO (LCZ696) shown to reduce the risk of cardiovascular death and hospitalization approved by Health Canada 44 Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37 45 Sep 25, 2015: Novartis' new heart failure medicine Entresto recommended by CHMP for EU approval 46 Sep 18, 2015: Swissmedic approves Novartis' new heart failure medicine Entresto 47 Jul 07, 2015: Novartis' new heart failure medicine LCZ696, now called Entresto, approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization 47 Jun 22, 2015: New Drug, LCZ696, Show Promise for Treating Your Heart Failure 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by Novartis AG, H1 2016 20 Pipeline by Pharmaleads SA, H1 2016 21 Pipeline by Theravance Biopharma, Inc., H1 2016 22 Dormant Projects, H1 2016 35 Discontinued Products, H1 2016 36


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Actions, H1 2016 15 Number of Products by Routes of Administration, H1 2016 16 Number of Products by Stage and Routes of Administration, H1 2016 16 Number of Products by Molecule Types, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 18

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected to

Read More...

Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to dri

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify